Ependymoma: new therapeutic approaches including radiation and chemotherapy.
Recent advances in neuroimaging, neurosurgery and radiation therapy have improved disease control and functional outcomes for children with ependymoma, including children under the age of 3 years. The rate of gross-total resection has been increased to 85% in some series and 3 year progression-free survival after radiation therapy as high as 75% has been reported along with significant reductions in neurologic, endocrine and cognitive deficits. Based on these advances and renewed interest in radiation therapy as a frontline treatment modality, attention has been refocused on disease control instead of radiotherapy avoidance. Future research in the treatment of this tumor, that afflicts fewer than 200 children in the US each year, will focus on molecular biology, clarifying risk factors for tumor control and late effects, and testing novel agents.
Merchant
Thomas E
TE
Division of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. thomas.merchant@stjude.org
Fouladi
Maryam
M
D000367:Age Factors; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D003072:Cognition Disorders; D018450:Disease Progression; D004806:Ependymoma / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000209:etiology; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008279:Magnetic Resonance Imaging; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011832:Radiation Injuries; D012307:Risk Factors; D013534:Survival